Drug Database
TR

transdermal DDS (Latitude / transdermal DDS, 3M / TDDS)

✓ Approved

3M Pharmaceuticals · Small Molecule · Small Molecule

What is transdermal DDS?

transdermal DDS is a small molecule developed by 3M Pharmaceuticals. It is approved for therapeutic indications via transdermal.

Drug Profile

Brand NamesLatitude, transdermal DDS, 3M, TDDS
Company3M Pharmaceuticals
Drug ClassSmall Molecule
RouteTransdermal
StatusApproved

Therapeutic Indications

transdermal DDS is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedAdvances in radiation oncology2026-08-30

Systemic Copper Chelation Reduces Collagen Deposition and Preserves Secretory Function in Irradiated Mouse Salivary Glands.

Nam Kihoon K, Maslow Frank M FM, Santos Harim Tavares Dos HTD, Shanbhag Vinit C VC et al.

Radiation therapy (RT) for head and neck cancer commonly causes fibrosis of the salivary gland (SG) and loss of secretory function. We previously demonstrated that transdermal injection of the copper chelator tetrathiomolybdate into irradiated submandibular glands reduced the early deposition of fibrillar collagen and preserved their integrity and function. Although these studies identified copper metabolism as a novel therapeutic target to control RT-induced damage to the SG, local delivery of copper chelators in human SG presents clinical hurdles including specialized personnel and equipment needed for administration together with the discomfort felt by patients upon receiving this treatment. To overcome these issues, the current study investigated whether systemic administration of tetrathiomolybdate (TTM) via drinking water could similarly reduce collagen deposition and preserve secretory function. Mice received TTM in drinking water (0.1 mg/mL) beginning 7 days before and continuing through 7 days after a single 15-Gy dose of RT to the neck. Systemic TTM exposure and copper bioavailability were assessed by measuring molybdenum and copper levels and serum ceruloplasmin activity. RT-induced SG injury was evaluated by collagen deposition, histopathology, epithelial integrity, and stimulated saliva secretion. Systemically administered TTM reached the submandibular gland and reversibly reduced copper bioavailability, as demonstrated by increased molybdenum levels, reduced copper-to-molybdenum ratios, and suppression of serum ceruloplasmin activity. Moreover, TTM treatment attenuated RT-induced collagen deposition and epithelial damage and promoted recovery of ZO-1 expression. Finally, at 30 days after RT, stimulated saliva flow was significantly higher in TTM-treated irradiated mice than in irradiated mice receiving regular water. Systemic TTM administration reduces copper bioavailability, attenuates RT-induced collagen deposition and epithelial injury, and preserves SG secretory function. These findings support systemic copper chelation as a less invasive alternative to local TTM delivery for limiting RT-induced SG damage.

PubMedQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2026-08-29

Mapping the Problem Areas in Diabetes (PAID) and Diabetes Distress Scale (DDS) to the EQ-5D-5L in diabetes care.

Arija Pablo P, Durno Nicholas N, Wang Jie J, Kittel Phillip P et al.

To develop and validate mapping algorithms that estimate EQ-5D health state utility values (HSUVs) from two diabetes-specific patient-reported outcome measures, the Problem Areas in Diabetes (PAID) and Diabetes Distress Scale (DDS), to support economic evaluations when EQ-5D data are unavailable. Data from 662 adults with diabetes in Germany included PAID-20, DDS-17, and EQ-5D-5L responses. Direct mapping models predicted EQ-5D utilities using Tobit and censored least absolute deviation (CLAD) regressions, while indirect mapping models used proportional and partial proportional odds regressions to predict EQ-5D dimensions. Six model specifications were tested, incorporating PAID and DDS items with covariates (age, sex, diabetes type), with selection of predictors guided by item correlations and backward stepwise procedure to retain statistically relevant variables. Model performance was assessed using a selection of performance metrics including root mean square error (RMSE) and mean absolute error (MAE). Internal validation of the models employed 10-fold cross-validation. The strongest-performing direct mapping models consisted of a model with a selection of PAID-20 items and covariates (Tobit regression; RMSE: 0.159; MAE: 0.117) and a model that incorporated PAID-20, DDS-17, and covariates (CLAD regression; RMSE: 0.146; MAE: 0.09), and a model based on DDS-17 items and covariates (Tobit regression; RMSE: 0.164; MAE: 0.121). Indirect mapping models demonstrated higher prediction errors overall (RMSE: 0.187-0.21; MAE: 0.124-0.141) than their counterparts. We present novel algorithms that enable estimation of EQ-5D utilities from PAID and DDS scores, facilitating economic evaluation in diabetes. Preferred models demonstrated predictive accuracy comparable to published mapping studies.

PubMedAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026-08-29

Integrated O2 and H2 Gas Therapy via Microneedle-Assisted Photocatalytic Water Splitting for Accelerating Diabetic Full-Thickness Skin Wound Healing.

Chen Zesheng Z, Yu Yanchao Y, Xiao Xingyuan X, Cheng Wenwen W et al.

Impaired wound healing in diabetes is closely associated with cellular ferroptosis. Microneedle-assisted gas therapy exerts molecular regulation of ferroptosis, representing a promising approach for accelerating diabetic wound healing. To date, O2 and H2 gas therapies have consistently been conducted independently and have never been integrated into a single system. Whether and how their synergy might be realized remains a defining challenge. Herein, we propose a concept of integrated O2 and H2 gas therapy, demonstrated by fabricating a gas-producing microneedle material. Platinum@MIL-101(Fe)-NH2@phosphotungstic acid (PMP) nanoparticles are synthesized as a visible light-driven photocatalyst for H2 and O2 co-evolution. The rational design of a spatially separated structure boosts their photocatalytic efficiency under physiological conditions. PMP nanoparticles are further incorporated with bilayer gelatin methacryloyl (GelMA)/PMP composite microneedles (denoted as GPM microneedles). The obtained GPM microneedles enable transdermal delivery of PMP nanoparticles for integrated O2 and H2 gas therapy, and demonstrate desirable biocompatibility and pro-regenerative effects. The mechanism of integrated O2 and H2 gas therapy has been identified as a TNFAIP3/hnRNPA1 ubiquitination/ferroptosis signaling axis, establishing for the first time a direct link to ferroptosis. In conclusion, this study yields a transformative concept and a ferroptosis-targeting microneedle material with well-defined molecular mechanism for diabetic wound management.

PubMedExploration (Beijing, China)2026-08-28

The Needle-Free Frontier: Redefining the Limits of Transdermal Insulin Delivery.

Chen Junge J, Liu Yuxuan Y, Xia Bozhang B, Essola Julien Milon JM et al.

Wei and colleagues reported a pH-responsive, charge-switchable polyzwitterionic polymer carrier that achieves non-invasive transdermal insulin delivery without external energy input. The approach leverages adaptive compatibility with the cutaneous microenvironment to shuttle functional macromolecules across intact skin and achieve definitive systemic therapeutic outcomes.

PubMedAutism : the international journal of research and practice2026-08-28

Development of the Screening Tool for Autism in Two-Year-Olds-Brief Form: Accuracy in Detecting Autism in Toddlers.

Hung Yu-Ru YR, Hou Yuh-Ming YM, Iao Lai-Sang LS, Wu Chin-Chin CC

Early diagnosis of autism is crucial for timely intervention, yet existing screening tools are often limited by administration time in clinical settings. This study developed and evaluated the Screening Tool for Autism in Two-Year-Olds-Brief Form (STAT-BF) for detecting autism in toddlers aged less than 36 months. In Study 1, two independent samples of 40 toddlers each (20 autistic and 20 with developmental delays [DDs]) were analyzed using chi-square tests to identify discriminative items. Five items (Turn-taking, Bubbles, Snack, Balloon, and Bag of Toys) were retained, with a cutoff score of 3 yielding optimal sensitivity and specificity. Study 2's validation, based on a sample of 251 toddlers (81 autism, 55 mild- autism, 115 DDs), yielded high sensitivity for autism (0.91; 74/81) and mild-autism (0.91; 50/55), together with good specificity (0.81; 93/115). Administration time was reduced to 5 to 10 min while maintaining screening accuracy. These findings suggest that the STAT-BF may serve as a feasible and efficient Level 2 screening tool for early autism detection among toddlers referred for developmental concerns, particularly in resource-limited clinical settings. Further validation in diverse populations and longitudinal follow-up is warranted to establish generalizability.Lay AbstractEarly support can make a big difference in the outcomes of autistic children, but they must first be identified as early as possible. Although reliable autism screening tools exist, many are too time-consuming for high-volume clinical settings. In this study, we developed and validated a shorter version of the Screening Tool for Autism in Two-Year-Olds (STAT) that takes 5 to 10 min. This brief tool focuses on five play-based activities that assess social communication skills in toddlers aged 18 to 36 months. We conducted a two-phase study in Taiwan. The first phase identified the most discriminating items, and the validation phase included 251 toddlers with autism, mild-autism, and developmental delays (DDs). Results showed that the brief form correctly identified over 90% of autistic children, including those with milder symptoms, and correctly ruled out autism in about 80% of children with DDs. This efficient screening method could help more health care providers detect autism early, especially in high-volume clinical settings with limited resources. Because the brief form uses structured play instead of parent questionnaires, it offers direct behavioral observation and increases cultural accessibility for families from a broad range of backgrounds. This brief screening tool could help clinicians more efficiently identify autism among toddlers already referred for developmental evaluation, facilitating timely referral for formal diagnostic confirmation and subsequent access to intervention services.

PubMedPharmaceutical development and technology2026-08-28

Innovative Hybrid Microneedle Patch for Co-delivery of Varenicline and Melatonin: Development, Characterization, and Potential for Smoking Cessation.

Shahriari Mohammad Hassan MH, Salmani Hossein H, Ghiass Mohammad Adel MA, Kamali Nader N et al.

This study aimed to develop a microneedle patch loaded with varenicline and melatonin to improve patient compliance and enhance transdermal delivery for smoking cessation. Smoking remains a major public health challenge. While varenicline is effective, oral administration can cause adverse effects, and vaccine-like approaches are limited by nicotine's small size. A painless, microneedle patch delivering varenicline together with melatonin could improve patient adherence and provide sustained delivery. Microneedle arrays were fabricated using a blend of polyvinyl alcohol (PVA) and polyvinylpyrrolidone (PVP), with Tween-80 added to enhance varenicline solubility. Comprehensive mechanical characterization, including nanoindentation, scratch testing, and atomic force microscopy, was performed. In vitro drug release and transdermal permeation studies were conducted, complemented by histological evaluation and fluorescence imaging. The microneedles exhibited high hardness, flexibility, and uniform surface topography, enabling effective skin penetration. In vitro studies showed cumulative transdermal permeation of 34.3% for varenicline and 41.6% for melatonin over 48 hours. The dual-drug-loaded microneedles demonstrated a sustained release profile. Histological analysis confirmed the creation of microchannels without damaging surrounding tissues. The combination of varenicline and melatonin in the microneedle shows promise in overcoming the limitations of current smoking cessation therapies, offering a patient-friendly and effective intervention. Future studies should include comparisons with commercial therapies and ex vivo dissolution studies (Q8).

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about transdermal DDS